Cai Li

发表

Discovery and Pharmacology of a Novel Somatostatin Subtype 5 (SSTR5) Antagonist: Synergy with DPP-4 Inhibition.

Margaret S. Wu, Yun-ping Zhou, A. Howard, 2018, ACS medicinal chemistry letters.

Stimulation of Glucose-Dependent Insulin Secretion by a Potent, Selective sst3 Antagonist.

Margaret S. Wu, Yun-ping Zhou, A. Howard, 2012, ACS medicinal chemistry letters.

Effects of small interfering RNA-mediated hepatic glucagon receptor inhibition on lipid metabolism in db/db mice[S]

Shirly Pinto, T. Roddy, Kristian K. Jensen, 2013, Journal of Lipid Research.

Evidence that inhibition of insulin receptor signaling activity by PC-1/ENPP1 is dependent on its enzyme activity.

I. Wang, J. Berger, P. Lu, 2009, European Journal of Pharmacology.

Suppression of PC-1/ENPP-1 expression improves insulin sensitivity in vitro and in vivo.

Margaret S. Wu, I. Wang, J. Berger, 2009, European journal of pharmacology.

Investigation of Cardiovascular Effects of Tetrahydro-β-carboline sstr3 antagonists.

Margaret S. Wu, M. Reibarkh, Yun-ping Zhou, 2014, ACS medicinal chemistry letters.

Design and synthesis of a new class of malonyl-CoA decarboxylase inhibitors with anti-obesity and anti-diabetic activities.

Margaret S. Wu, Michael E. Lassman, J. Berger, 2010, Bioorganic & medicinal chemistry letters.

Design of potent and selective GPR119 agonists for type II diabetes.

A. Howard, P. Meinke, G. Chicchi, 2011, Bioorganic & medicinal chemistry letters.

Chronic Inhibition of Dipeptidyl Peptidase-4 With a Sitagliptin Analog Preserves Pancreatic β-Cell Mass and Function in a Rodent Model of Type 2 Diabetes

Yue Feng, Yun-ping Zhou, D. Moller, 2006, Diabetes.

The Discovery of MK-4256, a Potent SSTR3 Antagonist as a Potential Treatment of Type 2 Diabetes.

Margaret S. Wu, Rebecca T. Ruck, M. Reibarkh, 2012, ACS medicinal chemistry letters.

Inhibition of DPP-4 with sitagliptin improves glycemic control and restores islet cell mass and function in a rodent model of type 2 diabetes.

Yun-ping Zhou, N. Thornberry, J. Mu, 2009, European journal of pharmacology.

AMPK: an emerging drug target for diabetes and the metabolic syndrome.

Gaochao Zhou, Bei B. Zhang, Cai Li, 2009, Cell metabolism.

APPL1 mediates adiponectin-induced LKB1 cytosolic localization through the PP2A-PKCzeta signaling pathway.

F. Liu, R. DeFronzo, N. Musi, 2011, Molecular endocrinology.

SAR exploration at the C-3 position of tetrahydro-β-carboline sstr3 antagonists.

Margaret S. Wu, M. Reibarkh, Yun-ping Zhou, 2016, Bioorganic & medicinal chemistry letters.

Discovery of MK-1421, a Potent, Selective sstr3 Antagonist, as a Development Candidate for Type 2 Diabetes

Margaret S. Wu, Yun-ping Zhou, E. Sherer, 2015, ACS medicinal chemistry letters.

Effects of small interfering RNA-mediated hepatic glucagon receptor inhibition on lipid metabolism in db/db mice[S]

Shirly Pinto, T. Roddy, Kristian K. Jensen, 2013, Journal of Lipid Research.

Evidence that inhibition of insulin receptor signaling activity by PC-1/ENPP1 is dependent on its enzyme activity.

I. Wang, J. Berger, P. Lu, 2009, European journal of pharmacology.